We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 22, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023 , at 11:00 a.m.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company’s Board of Directors.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 8, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2023-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Cowen 43 rd Annual Health Care Conference on Monday, March 6, 2023
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 22, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the European Medicines Agency (EMA) granted Orphan Drug Designation to SAGE-718 for the treatment of
U.S. Food and Drug Administration (FDA) accepts filing of New Drug Application (NDA) for zuranolone and grants Priority Review in the treatment of Major Depressive Disorder (MDD) and Postpartum Depression (PPD) following submission of rolling NDA in December 2022 Robust pipeline advancing nine
Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Thursday, February 16, 2023 at 8:00 a.m.
Robust pipeline provides potential for long-term value creation, establishing Sage as a leader in brain health Rolling New Drug Application (NDA) submission for zuranolone in MDD and PPD complete, with potential for PDUFA date as early as the third quarter of 2023 if priority review is received and
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2023-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January